An Open-Label, Flexible-Dose Study of Olanzapine in the Treatment of Trichotillomania
J Clin Psychiatry 2003;64:49-52
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Thus far, only selective serotonin
reuptake inhibitors have been systematically studied in the
treatment of trichotillomania, and the results are conflicting.
This open-label study is the first to systematically evaluate an
atypical neuroleptic, olanzapine, as a monotherapy in the
treatment of trichotillomania.
Method: Twenty-one patients were screened and 18
patients were enrolled in a 3-month open-label study of
olanzapine for trichotillomania (diagnosis based on modified
DSM-IV criteria). Patients with comorbid psychiatric disorders or
on treatment with psychoactive medication were excluded.
Olanzapine was titrated gradually in 2.5-mg/week increments up to
a maximum dose of 10 mg/day.
Results: Seventeen patients who completed at
least 1 week of olanzapine treatment were evaluated. Hair
pulling, as measured by the Massachusetts General Hospital
Hairpulling Scale, decreased by 66% from baseline (p<=.001),
and mean scores on the Hamilton Rating Scale for Anxiety
decreased by 63% (p<=.05). Clinical Global Impressions scale
scores also revealed significant improvement as a whole
(p<=.001), with 4 patients having complete symptom remission
at the end of the study period.
Conclusion: Findings suggest that olanzapine may
be an effective monotherapy for trichotillomania.